Galderma’s Differin product line has been expanded with the FDA approval of Differin Lotion (adapalene lotion) 0.1% for the treatment of acne vulgaris in patients ≥12 years of age. This approval was based on data from two 12-week, multicenter, controlled clinical studies of similar design, comparing Differin Lotion 0.1% to vehicle in 2,141 patients with acne. Differin Lotion 0.1% demonstrated statistically significant reductions in total, inflammatory, and non-inflammatory lesion count at week 12 compared to vehicle, respectively.
Differin Lotion is expected to be available in April 2010.
For more information call (866) 735-4137 or visit www.differin.com.